Crucell’s strong product portfolio is supported by a range of patented technologies. Our cutting-edge technology platforms enable the cost-effective discovery, development and production of a range of biopharmaceutical products, including innovative vaccines, therapeutic proteins and gene therapies. In therapeutic areas where Crucell does not plan to develop its own products, these proprietary technologies may be licensed out to other biopharmaceutical manufacturers or research groups.

Five core proprietary technology platforms

Crucell has five core proprietary technology platforms:

1. PER.C6® technology: a comprehensive package of technology and know-how based on our human PER.C6 cell line. It provides a safe and cost-effective manufacturing system for high-yield, large-scale production of vaccines, recombinant proteins including monoclonal antibodies, and gene therapy products.
2. AdVac® technology: a technology based on the development and production of novel adenovirus vectors. It can be used together with PER.C6® technology to develop recombinant vaccines against life-threatening diseases or to develop gene therapy products.
3. MAbstract® technology: a human-based antibody phage display technology that facilitates the discovery of novel drug targets and the identification of human monoclonal antibodies against those targets.
4. STAR® technology: a gene expression technology that enhances yields of recombinant human antibodies and therapeutic proteins on mammalian cells lines.
5. Virosome technology: a virosome is a virus-like particle that acts as a vaccine adjuvant and carrier system. Vaccines based on virosome technology combine high efficacy with high purity, and therefore low potential for causing side-effects.

Support technologies

In addition to our five core technologies, Crucell has developed a number of other technologies that support biopharmaceutical innovation. These include:

• Recombinant Paramyxovirus technology: a novel vaccine design technology based on recombinant measles vectors. These vaccine vectors can be manufactured economically in large quantities, and induce strong and sustained immune responses against the antigens they carry.
• Hansenula polymorpha technology: an innovative yeast-based production platform widely used for the manufacture of industrial proteins, food and feed additives, and highly immunogenic vaccines—such as Crucell’s Hepavax-Gene® vaccine against hepatitis B.

Quick Links

Products

R&D

Partners